Trial Profile
Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.
- 27 Feb 2018 Primary endpoint has been met. (To assess the efficacy of the WT1 peptide vaccine administered to patients in CR from AML.), as reported in a Sellas Life Sciences media release.
- 27 Feb 2018 According to a Sellas Life Sciences media release, results from this trial published in the current issue of Blood Advances.